Groundbreaking migraine treatment offers ‘new hope’ for patients
A treatment for acute migraines has been approved for NHS use for the first time, with experts saying the move could be a “step-change” for thousands of people who suffer from the condition. The National Institute for Health and Care Excellence (Nice) said its final draft guidance on Rimegepant “addresses the high unmet need for treatment options for acute migraine”. Rimegepant, also known as Vydura and made by Pfizer, will be available to adults who have tried at least two triptans – medication usually given to tackle headaches or migraines – but found they did not work well enough. It can also be administered to those who are not able to take triptans or have an intolerance, or patients who have tried nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol. Helen Knight, director of medicines evaluation at Nice, said: “Migraine is a condition described in comments to Nice from carers and people with migraine as an invisible disability that affects all aspects of life including work, education, finances, mental health, social activities and family. “Today’s final draft guidance addresses the high unmet need for treatment options for acute migraine, once again demonstrating our ability to ensure clinically and cost-effective medicines are available to those who need them as quickly as possible.” Rimegepant is taken as a wafer, which dissolves under the tongue and works by stopping the release of a protein around the brain called calcitonin gene-related peptide. In July, the medicine was recommended as an option for preventing episodic migraines in adults who have at least four and fewer than 15 attacks per month if “at least” three other treatments have not worked. This is the first and only Nice-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment Helen Knight, Nice Under the latest guidance, it will also be used to relieve symptoms of a migraine, which can include pain, nausea and sensitivity to light, but also painless symptoms such as temporary visual disturbances known as “aura”, which Nice said “is not well managed with existing treatments”. The recommendation is expected to benefit about 13,000 people. Ms Knight added: “This is the first and only Nice-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment.” Migraine is an incredibly misunderstood condition that can have a significant impact on all areas of life, including ability to work, maintain relationships and mental health Robert Music, The Migraine Trust Robert Music, chief executive of The Migraine Trust, said the Nice guidance “provides people with migraine valuable options to help reduce the pain and length of a migraine attack”. “It brings new hope,” he added. “It will especially benefit those who have not found a treatment that works, those who get debilitating side effects – including medicine overuse headache – from them, and those with cardiovascular disease who cannot take existing treatments. “Migraine is an incredibly misunderstood condition that can have a significant impact on all areas of life, including ability to work, maintain relationships and mental health.” Read More NHS winter resilience fund announced by Government NHS reliance on paper notes ‘stopping trusts from realising full potential’ Recession fears as UK economy shrinks by more than expected in shock decline Charity boss speaks out over ‘traumatic’ encounter with royal aide Ukraine war’s heaviest fight rages in east - follow live
2023-09-14 11:57
DeSantis warns against Covid-19 boosters for people under 65 contradicting CDC guidance
Florida Gov. Ron DeSantis' administration is advising people under the age of 65 against getting the new Covid-19 booster shots from Pfizer/BioNTech and Moderna, contradicting federal health officials' guidance.
2023-09-14 11:50
Australian lender NAB to close Hong Kong office
By Navya Mittal and Echha Jain National Australia Bank (NAB) said on Thursday it would shut its Hong
2023-09-14 11:48
Son of Aung Sang Suu Kyi is worried about her health in detention and about Myanmar's violent crisis
The son of ousted Myanmar leader Aung Sang Suu Kyi says he has always avoided talking to the media, but this time is different
2023-09-14 11:47
Guatemalan president-elect suspends presidential transition process
Guatemalan President-elect Bernardo Arévalo de León has announced he is temporarily suspending the presidential transition process after Public Ministry agents raided electoral facilities and opened voting boxes.
2023-09-14 11:29
Dodgers' Walker Buehler says he wasn't recovering well enough after rehab start to return
Los Angeles Dodgers pitcher Walker Buehler says he shut down his comeback from Tommy John surgery this season because he wasn’t recovering well after a rehab start
2023-09-14 11:27
China to formulate 'special' measures to widen Taiwan's access to Fujian
BEIJING (Reuters) -China will take a number of "special" policy measures to improve access for Taiwanese enterprises to Fujian province
2023-09-14 11:21
Indonesia's August trade surplus seen widening to $1.55 billion - Reuters poll
JAKARTA Indonesia's trade surplus in August likely widened slightly from a month earlier amid falling imports, even as
2023-09-14 11:17
S.Korea central bank says coordinated efforts needed to deal with household debt
SEOUL South Korea's central bank said on Thursday it needs to make coordinated efforts to contain household debt,
2023-09-14 11:17
For several episodes this fall, '60 Minutes' will become 90 minutes
The famous stopwatch will still announce the show as “60 Minutes.”
2023-09-14 11:16
A 4-year-old police dog named Yoda detained fugitive Danilo Cavalcante, bringing an end to the exhaustive, nearly 2 week-long manhunt
Moments after law enforcement officials spotted convicted murderer Danilo Cavalcante's head peeking through the underbrush, they released a police dog who bit and subdued Cavalcante, leading to his apprehension nearly two weeks after he escaped prison, officials said.
2023-09-14 10:53
San Diego's Juan Soto joins elite company with 2-plus seasons of 30-plus HRs and 100-plus walks
Juan Soto of the San Diego Padres has gone deep against the Los Angeles Dodgers, making him the seventh player in major league history with two-plus seasons of 30 or more home runs and 100-plus walks before turning 25
2023-09-14 10:52
